Şizofreni Hastalarında Serum Ürik Asit, Serum Ürik Asit Kreatinin Ranlarının Hastalık Şiddeti Ve Metabolik Sendrom İle İlişkisi

Yıl 2024, , 122 - 128, 30.08.2024

Merve Akkuş , Kader Semra Karataş , Onur Gökçen , Feyza Dönmez , Çağla Özdemir

https://doi.org/10.30565/medalanya.1486564

Öz

Amaç: Bu araştırmanın amacı çok yönlü etiyopatogeneze sahip şizofrenide serum ürik asit (SUA) ve serum ürik asit/kreatinin oranı (SUA/Cre) ile hastalık şiddeti ve metabolik sendrom arasındaki ilişkiyi incelemektir.

Yöntem: Çalışmaya 120'si sağlıklı kontrol ve 120'si şizofreni hastası olmak üzere toplam 240 katılımcı dahil edilmiştir. Sosyodemografik, klinik ve laboratuvar verileri toplandı, kriterlere göre metabolik sendrom durumu değerlendirildi. SUA ve kreatinin düzeyleri ölçülmüş ve SUA/Cre oranı hesaplanmıştır. Hastalığın şiddeti Pozitif ve Negatif Sendrom Ölçeği (PANSS) kullanılarak değerlendirilmiştir. Korelasyon ve ilişkileri tespit etmek için istatistiksel analizler yapılmıştır.

Bulgular: SUA düzeyleri ve SUA/Cre oranı şizofreni hastalarında kontrol grubuna göre daha yüksekti (sırasıyla p=0.14, p=0.010). SUA/Cre oranı PANSS negatif skoru ile pozitif korelasyon gösterdi (r=0.266,p=0.03). SUA düzeyleri, metabolik sendromu da olan şizofreni tanılı bireylerde, metabolik sendromu olmayanlara kıyasla daha yüksekti (p=0.009). Doğrusal regresyon analizleri, SUA düzeyleri ve SUA/Cre oranı ile şizofreni arasındaki ilişkinin cinsiyet, yaş, metabolik sendrom, BMI ve sigara içmenin etkileri sabitlendiğinde de devam ettiğini göstermiştir.

Sonuç: Bu çalışma, şizofreni tanısı almış bireylerde SUA ve SUA/Cre oranının hastalık şiddeti ve metabolik sendrom ile ilişkisini vurgulamaktadır.

Anahtar Kelimeler

Şizofreni, Ürik asit, Ürik asit kreatinin oranı, Metabolik sendrom, Hastalık şiddeti

The Relationship of Serum Uric Acid, Serum Uric Acid Creatinine Ratios With Disease Severity and Metabolic Syndrome in Schizophrenia Patients

Öz

Aim: The objective of this research was to examine the association between serum uric acid (SUA) and serum uric acid/creatinine ratio (SUA/Cre), disease severity and metabolic syndrome in schizophrenia with a multifaceted etiopathogenesis.

Methods: The study comprised 240 participants in total, 120 of whom were healthy controls and 120 of whom were schizophrenia patients. Sociodemographic, clinical and laboratory data was collected and metabolic syndrome was assessed according to the established criteria. SUA and creatinine levels were measured and the SUA/Cre ratio was calculated. The severity of the disease was evaluated utilizing the Positive and Negative Syndrome Scale (PANSS). Statistical analyses were conducted to ascertain correlations and associations.

Results: SUA levels and SUA/Cre ratio higher in schizophrenia patients than controls (p=0.14, p=0.010, respectively). SUA/Cre ratio was positively correlated with PANSS negative score (r=0.266, p=0.03). SUA levels were elevated in individuals diagnosed with schizophrenia who also had metabolic syndrome, in comparison to those who did not have metabolic syndrome (p=0.009). Linear regression analyses showed that the association between SUA levels and SUA/Cre ratio and schizophrenia persisted when the effects of gender, age, metabolic syndrome, BMI and smoking were fixed.

Conclusions: This study highlights the association of SUA and SUA/Cre ratio with disease severity and metabolic syndrome among individuals diagnosed with schizophrenia.

Anahtar Kelimeler

Schizophrenia, Uric acid, Uric acid creatinine ratio, Metabolic syndrome, Disease severity

Etik Beyan

The research received approval from the Ethics Committee of XXX University (2023/01-24). Each participant provided written informed permission to participate in this research.

Destekleyen Kurum

None

Kaynakça

• 1. Volkan K. Schizophrenia: Epidemiology, causes, neurobiology, pathophysiology, and treatment. Journal of Health Medical Sciences. 2020;3(4):487-521. DOI: 10.31014/aior.1994.03.04.143.
• 2. Fišar Z. Biological hypotheses, risk factors, and biomarkers of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2023;120:110626. DOİ: 10.1016/j.pnpbp.2022.110626.
• 3. He Q, You Y, Yu L, et al. Uric acid levels in subjects with schizophrenia: A systematic review and meta-analysis. Psychiatry Res. 2020;292:113305.DOİ: 10.1016/j.psychres.2020.113305.
• 4. Yao JK, Reddy R, van Kammen DP. Reduced level of plasma antioxidant uric acid in schizophrenia. Psychiatry Res. 1998;80(1):29-39.DOİ: 10.1016/s0165-1781(98)00051-1.
• 5. Black CN, Bot M, Scheffer PG, Snieder H, Penninx BW. Uric acid in major depressive and anxiety disorders. J Affect Disord. 2018;225:684-90. DOİ: 10.1016/j.jad.2017.09.003.
• 6. Solberg DK, Refsum H, Andreassen OA, Bentsen H. A five-year follow-up study of antioxidants, oxidative stress and polyunsaturated fatty acids in schizophrenia. Acta Neuropsychiatr. 2019;31(4):202-12. DOİ: 10.1017/neu.2019.14.
• 7. Gültekin BK, Kesebir S, Kabak SG, Ergün FF, Tatlidil Yaylaci E. Are Uric Acid Levels Different from Healthy Subjects in Bipolar Affective Disorder and Schizophrenia?: Relationship Between Clinical Improvement and Episode Severity in Male Patients. Noro Psikiyatr Ars. 2014;51(3):229-32. DOI: 10.4274/npa.y6827.
• 8. Belete R, Ataro Z, Abdu A, Sheleme M. Global prevalence of metabolic syndrome among patients with type I diabetes mellitus: A systematic review and meta-analysis. Diabetol Metab Synd. 2021;13(1):25. DOI: 10.1186/s13098-021-00641-8.
• 9. Ban TA. Fifty years chlorpromazine: a historical perspective. Neuropsychiatr Dis Treat. 2007;3(4):495-500. PMID: 19300578
• 10. Cohn TA, Remington G, Zipursky RB, Azad A, Connolly P, Wolever TM. Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: A preliminary report. Can J Psychiatry. 2006;51(6):382-6. DOI: 10.1177/070674370605100608.
• 11. Wang A, Tian X, Wu S, et al. Metabolic factors mediate the association between serum uric acid to serum creatinine ratio and cardiovascular disease. J Am Heart Assoc. 2021;10(23):e023054. DOI: 10.1161/JAHA.121.023054.
• 12. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-76. DOI: 10.1093/schbul/13.2.261.
• 13. Erkoç Ş, Arkonaç O, Ataklı C, Özmen E. The Reliability and Validit of Scale for the Assesment of the Positive Symtoms. (Pozitif semptomları değerlendirme ölçeğinin güvenilirliği ve geçerliliği.) Düşünen Adam. 1991;4(2):20-4.
• 14. Detection NCEPEPo, Adults ToHBCi. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III): The Program; 2002.
• 15. Shaker NM, Serafi De, Mahfouz RHELD, abd el moneam MHE-d. Exploring the role of serum uric acid as a biomarker in patients with schizophrenia, bipolar affective disorder, and major depressive disorder. Middle East Current Psychiatry. 2023;30(1):31. DOI: 10.1186/s43045-023-00307-3.
• 16. Lu Z, Wen T, Wang Y, Kan W, Xun G. Peripheral non-enzymatic antioxidants in patients with schizophrenia: a case-control study. BMC Psychiatry. 2020;20(1):241. DOI: 10.1186/s12888-020-02635-8.
• 17. Reddy R, Keshavan M, Yao JK. Reduced plasma antioxidants in first-episode patients with schizophrenia. Schizophr Res. 2003;62(3):205-12. DOI: 10.1016/s0920-9964(02)00407-3.
• 18. Malewska-Kasprzak MK, Permoda-Osip A, Rybakowski J. Disturbances of purinergic system in affective disorders and schizophrenia. Psychiatr Pol. 2019;53(3):577-87. DOI: 10.12740/pp/97335.
• 19. Godin O, Leboyer M, Gaman A, et al. Metabolic syndrome, abdominal obesity and hyperuricemia in schizophrenia: Results from the FACE-SZ cohort. Schizophr Res. 2015;168(1-2):388-94. DOI: 10.1016/j.schres.2015.07.047.
• 20. Gu L, Huang L, Wu H, Lou Q, Bian R. Serum uric acid to creatinine ratio: a predictor of incident chronic kidney disease in type 2 diabetes mellitus patients with preserved kidney function. Diab Vasc Dis Res. 2017;14(3):221-5. DOI: 10.1177/1479164116680318.
• 21. Borovcanin MM, Janicijevic SM, Mijailovic NR, Jovanovic IP, Arsenijevic NN, Vesic K. Uric acid potential role in systemic inflammation and negative symptoms after acute antipsychotic treatment in schizophrenia. Front Psychiatry. 2022;12:822579. DOI: 10.3389/fpsyt.2021.822579.
• 22. Goldsmith DR, Haroon E, Miller AH, Strauss GP, Buckley PF, Miller BJ. TNF-α and IL-6 are associated with the deficit syndrome and negative symptoms in patients with chronic schizophrenia. Schizophr Res. 2018;199:281-4. DOI: 10.1016/j.schres.2018.02.048.
• 23. Haj Mouhamed D, Ezzaher A, Neffati F, Douki W, Gaha L, Najjar MF. Effect of cigarette smoking on plasma uric acid concentrations. Environ Health Prev Med. 2011;16(5):307-12. DOI: 10.1007/s12199-010-0198-2.
• 24. Jeong H, Moon JE, Jeon CH. Hyperuricemia is associated with an increased prevalence of metabolic syndrome in a general population and a decreased prevalence of diabetes in men. J Rheum Dis. 2020;27(4):247-60. DOI: 10.4078/jrd.2020.27.4.247.
• 25. Chiu C-C, Chen C-H, Huang M-C, Chen P-Y, Tsai C-J, Lu M-L. The relationship between serum uric acid concentration and metabolic syndrome in patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol. 2012;32(5):585-92. DOI: 10.1097/JCP.0b013e3182664e64.